Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584905 | 0.89 | KMT2A (0.50) | KMT2AMEN1SLC22A12MAPTTP53 | |
| SCHEMBL5584235 | 0.87 | KMT2A (0.50) | KMT2AMEN1MAPTTP53RORC | |
| SCHEMBL5584459 | 0.86 | KMT2A (0.49) | KMT2AMEN1SLC22A12MAPTTP53 | |
| SCHEMBL5584290 | 0.82 | KMT2A (0.46) | KMT2AMEN1SLC22A12MAPTTP53 | |
| SCHEMBL5584204 | 0.82 | KMT2A (0.46) | KMT2AMEN1MAPTTP53ALDH1A1 | |
| SCHEMBL5585232 | 0.81 | KMT2A (0.45) | KMT2AMEN1MAPTTP53ALDH1A1 | |
| SCHEMBL5584504 | 0.81 | KMT2A (0.42) | KMT2AMEN1MAPTTP53CNR2 | |
| SCHEMBL5584145 | 0.79 | KMT2A (0.43) | KMT2AMEN1MAPTTP53CNR2 | |
| SCHEMBL5584388 | 0.79 | ALDH1A1 (0.44) | KMT2AMEN1MAPTTP53ALDH1A1 | |
| SCHEMBL5584862 | 0.78 | KMT2A (0.43) | KMT2AMEN1MAPTTP53CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861428-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | KMT2A 3413/4885MEN1 4656/4885SLC22A12 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.